home All News open_in_new Full Article

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States  GlobeNewswire


today 13 h. ago attach_file Politics

attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Events
attach_file Events
attach_file Economics
attach_file Politics
attach_file Events
attach_file Politics
attach_file Politics
attach_file Events
attach_file Politics


ID: 2792323990
Add Watch Country

arrow_drop_down